How does the IgE Surpass ELISA Kit analyze the core role of immunoglobulin E in allergies and diseases?

1. What is the unique molecular structure and biosynthetic pathway of Immunoglobulin E (IgE)?

Immunoglobulin E (IgE) is one of the five classes of immunoglobulins (IgG, IgA, IgM, IgD, IgE) and plays a critical role in immune responses, particularly in allergic reactions. Unlike other antibodies, IgE has a monomeric structure with heavy chains (ε chains) containing four constant regions (Cε1-Cε4) instead of the usual three. This unique Cε2 constant region gives it a molecular weight of approximately 190 kDa. Its biosynthesis begins in B cells through a T cell-dependent "class switch recombination" process. This requires two signals: the first signal is provided by cytokines IL-4 and IL-13 produced by Th2 cells, activating the transcription factor STAT6; the second signal comes from the binding of CD40 on B cells to CD40 ligand on T cells, activating the NF-κB pathway. Together, these signals drive B cells to switch from producing IgM to producing IgE with the same antigen specificity. Notably, IgE is produced not only in systemic lymphoid tissues (e.g., tonsils) but also locally in mucosal tissues (e.g., respiratory and gastrointestinal tracts), a phenomenon (local allergy) closely linked to the pathogenesis of chronic rhinitis and severe asthma.

2. How does IgE mediate immediate hypersensitivity and immune regulation through its receptors?

IgE functions primarily through its high-affinity and low-affinity receptors. The high-affinity receptor FcεRI is mainly expressed on mast cells and basophils. When multivalent allergens cross-link with specific IgE bound to these cells, it triggers FcεRI clustering and activation, leading to rapid degranulation and release of preformed mediators (e.g., histamine, tryptase) and newly synthesized leukotrienes, prostaglandins, and cytokines (e.g., IL-4, IL-5, IL-13). These mediators cause vasodilation, smooth muscle contraction, and mucus secretion, forming the basis of the early- and late-phase reactions in allergic rhinitis, asthma, food allergies, and systemic anaphylaxis. The low-affinity receptor CD23 (FcεRII) is widely expressed on B cells, antigen-presenting cells, and others, regulating IgE synthesis (negative feedback), antigen capture, and presentation. Circulating IgE levels can upregulate both receptors, creating a positive feedback loop.

3. What disease states are associated with elevated serum total IgE levels?

Quantitative measurement of serum total IgE is a key clinical indicator for assessing allergic diseases and related conditions. Elevated levels are primarily seen in:

1. Allergic diseases: The most common association, including atopic dermatitis, allergic asthma, and allergic bronchopulmonary aspergillosis. High IgE levels often indicate atopy.

2. Parasitic infections: Especially in resource-limited regions, helminth infections are a major cause of significantly elevated IgE.

3. Primary immunodeficiency disorders: Many inborn errors of immunity are accompanied by hyper-IgE, such as STAT3-mutated hyper-IgE syndrome (Job syndrome) and WAS protein deficiency causing Wiskott-Aldrich syndrome, characterized by extremely high IgE levels (often >2000 IU/mL).

4. Other diseases: Including eosinophilic granulomatosis with polyangiitis, certain lymphomas (e.g., Hodgkin's lymphoma), viral infections (e.g., EBV), inflammatory diseases, and post-renal transplant states. Smoking and alcohol consumption have also been linked to elevated serum IgE.

4. What are the mechanisms and clinical significance of anti-IgE targeted therapy (e.g., omalizumab)?

Anti-IgE monoclonal antibodies like omalizumab are a cornerstone of targeted therapy for allergic diseases. They work by specifically binding the Cε3 domain of free IgE, which is critical for IgE's interaction with FcεRI. By forming inactive immune complexes, omalizumab reduces circulating "free" IgE levels, preventing its binding to mast cells and basophils, thereby blocking the initiation of allergic cascades. This therapy is approved for moderate-to-severe allergic asthma and chronic spontaneous urticaria and shows promise for other IgE-mediated conditions. Notably, during omalizumab treatment, total serum IgE levels (including drug-bound forms) artificially increase, making conventional total IgE tests unreliable for assessing bioactive free IgE.

5. What is the clinical and research value of the IgE Surpass ELISA Kit?

The IgE Surpass ELISA Kit is a high-sensitivity, high-specificity quantitative tool with core applications:

1. Allergy diagnosis and monitoring: It accurately measures total IgE in serum, aiding in assessing allergic status and severity. For allergen-specific IgE, it is foundational for diagnosing specific sensitizations.

2. Treatment evaluation: Baseline total IgE is required before starting anti-IgE therapy (e.g., omalizumab) to determine dosing. During treatment, specialized methods (or indirect markers) are needed to assess response, as total IgE becomes artificially elevated.

3. Immunodeficiency diagnosis: Abnormally high total IgE is a key lab clue for suspected hyper-IgE syndromes.

4. Research and mechanistic studies: The kit provides reliable quantitative data for studying allergy mechanisms, evaluating new drugs' effects on IgE, and exploring IgE dynamics in diseases.

Thus, the IgE Surpass ELISA Kit bridges IgE biology and clinical phenotypes, enabling personalized diagnosis, treatment decisions, and research.

6. Which manufacturers provide the IgE Surpass ELISA Kit?

Hangzhou Start Biological Technology Co., Ltd. has independently developed the "Rat IgE Surpass ELISA PairSet Kit" (Catalog No.: S0H2016), a core reagent set designed for developing high-sensitivity, high-specificity rat IgE quantitative assays. This kit provides rigorously paired and validated capture/detection antibody pairs, enabling rapid development of high-performance sandwich ELISA for accurately quantifying IgE in rat serum, plasma, cell culture supernatants, and more. It is ideal for allergy/parasite immunity research, type I hypersensitivity model evaluation, and immunotoxicology studies.

Technical support: Detailed documentation includes antibody validation data, ELISA protocols (coating, blocking, detection), buffer recipes, and standard curve guidelines. Expert method development support is available.

Hangzhou Start Biological Technology is committed to providing high-performance, high-value core reagents for immunology research, disease models, and bioassays. For details on the "Rat IgE Surpass ELISA PairSet Kit" (Catalog No. S0H2016), technical documents, or samples, please contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.